Understanding DNA Methylation in Glioblastoma and Biological Sex Differences

Glioblastoma represents one of the most aggressive and lethal primary brain malignancies encountered in neuro-oncology practice. Epidemiological data consistently reveal marked disparities in glioblastoma incidence and patient survival based on biological sex. Specifically, male individuals develop glioblastoma at higher rates and experience shorter overall survival compared to females. While clinicians have recognized these demographic disparities for decades, researchers only recently began elucidating the underlying molecular mechanisms. Emerging evidence highlights fundamental differences in gene expression programs between male and female patients. Epigenetic modifications, particularly DNA methylation, regulate gene expression without altering the underlying genomic sequence. Therefore, profiling DNA methylation in glioblastoma provides vital insights into how sex-biased epigenetic landscapes drive tumor aggressiveness. Understanding these epigenomic distinctions enables clinicians to comprehend why standard treatments yield variable responses across sexes. Furthermore, identifying unique sex-specific epigenetic signatures helps neuro-oncologists refine patient risk stratification. In clinical settings, precision oncology relies on robust molecular classifiers to predict disease trajectory accurately. Consequently, exploring the epigenome bridges critical knowledge gaps between molecular pathology and clinical neurosurgery. By recognizing that male and female glioblastomas harbor distinct epigenetic architectures, clinicians can move closer to personalized, sex-informed therapeutic paradigms.

Unsupervised Clustering Identifies Distinct Epigenetic Profiles

To investigate sex-specific epigenetic variation, researchers analyzed 614 publicly available DNA methylation datasets. This comprehensive cohort comprised 252 female patients and 362 male patients diagnosed with primary or recurrent glioblastoma. The investigative team implemented a joint and individual variation explained computational framework. Consequently, this advanced unsupervised method separated shared genomic signals from sex-specific methylomic variance. Through this approach, the researchers identified two distinct epigenetic clusters within male patients and two separate clusters within female patients. Notably, these clusters emerged independently of conventional clinical confounders, such as patient age or tumor location. In male cohorts, the identified methylation clusters demonstrated a direct correlation with biological aggressiveness. Conversely, female tumors exhibited unique epigenetic patterns that reflected distinct transcriptional pathways. In addition, comparative methylome profiling revealed extensive differences in the regulation of developmental and immune-related genes. These computational discoveries demonstrate that glioblastoma is biologically heterogeneous not only across histological subtypes but also between biological sexes. Furthermore, unsupervised clustering proves that epigenetic changes actively define tumor behavior rather than functioning as passive bystanders. Ultimately, these findings underscore the necessity of evaluating epigenetic datasets separately for male and female patient cohorts.

Survival Outcomes and Sex-Specific Prognostic Biomarkers

The clinical relevance of these epigenetic clusters became particularly apparent during survival analyses. Kaplan-Meier survival curves and Cox proportional hazards models revealed significant prognostic divergence among male patients. Specifically, the two male epigenetic clusters exhibited markedly different overall survival rates. Male patients in the high-risk epigenetic subgroup experienced significantly accelerated tumor recurrence and poorer clinical outcomes. To translate these complex genome-wide observations into a practical diagnostic tool, investigators identified the 20 most consistently altered genes in males. Subsequently, they developed a targeted epigenetic biomarker panel based on these top differentially regulated loci. This streamlined panel successfully predicted overall survival in both male and female patients at initial surgical resection. Therefore, the panel effectively captured core epigenetic pathways governing tumor virulence across sexes. Moreover, multivariate analyses confirmed that this methylation panel retained independent prognostic value after adjusting for patient age and functional performance status. Because early prognostic stratification guides neuro-oncological management, such targeted panels offer immense potential for postoperative risk assessment. Consequently, identifying high-risk epigenetic profiles immediately after primary surgery allows clinicians to tailor adjuvant therapeutic intensity more effectively.

Validation in The Cancer Genome Atlas Cohort

Robust clinical translation requires thorough validation across independent multi-center patient populations. To confirm their findings, the investigators validated the sex-specific epigenetic signatures using data from The Cancer Genome Atlas. This independent validation cohort reinforced the reproducibility of the identified methylation clusters across diverse clinical settings. Furthermore, the targeted 20-gene panel consistently predicted overall survival in the external validation dataset. Thus, the analytical framework proved resilient against technical batch effects and platform variations commonly seen in multi-omics studies. In addition, the validation process confirmed that epigenetic differences between male and female glioblastomas are biologically stable. These reproducible methylomic alterations influence critical oncogenic pathways, including cell cycle checkpoint regulation, cellular senescence, and DNA repair mechanisms. Therefore, the prognostic power of the panel does not stem from statistical artifact but reflects genuine tumor biology. Consequently, neuro-oncologists can trust these biomarkers as dependable indicators of tumor behavior. Validating findings across diverse populations is essential for translating genomic discoveries into standardized molecular diagnostics. Ultimately, this validation establishes a solid foundation for incorporating sex-informed epigenetic biomarkers into routine neuropathological workflows.

Clinical Implications for Precision Neuro-Oncology

The discovery of sex-specific epigenetic subgroups carries profound implications for modern neuro-oncology. Current standard of care for glioblastoma involves maximal surgical resection followed by concurrent chemoradiation with temozolomide. However, therapeutic responses vary substantially among patients, even when controlling for known biomarkers like MGMT promoter methylation status. Integrating sex-specific epigenetic profiling into routine clinical evaluation could substantially improve individualized risk assessment. For instance, identifying a high-risk epigenetic profile enables multidisciplinary tumor boards to recommend closer radiographic surveillance or novel clinical trials. In addition, these epigenetic insights may explain why certain experimental therapies demonstrate divergent efficacy between men and women. Pharmacological agents targeting epigenetic regulators, such as histone deacetylase inhibitors or DNA methyltransferase inhibitors, could yield enhanced efficacy when tailored to sex-specific profiles. Moreover, clinicians can utilize these prognostic panels to facilitate transparent prognosis discussions with patients and their families. As precision neuro-oncology continues to evolve, incorporating biological sex as a fundamental biological variable becomes indispensable. Therefore, neurosurgeons and oncologists should advocate for molecular testing that accounts for sex-divergent methylomic patterns during treatment planning.

Future Directions in Epigenetic Stratification for Gliomas

Looking forward, prospective clinical trials must evaluate whether treatment stratification based on sex-specific epigenetic profiles improves patient survival. Researchers should investigate how these DNA methylation patterns interact with other established molecular features, including IDH mutation status and EGFR amplification. Furthermore, longitudinal studies assessing matched primary and recurrent tumors will clarify how epigenetic profiles evolve during adjuvant therapy. In addition, integrating liquid biopsy technologies, such as circulating cell-free DNA methylation assays, could enable non-invasive monitoring of these epigenetic signatures. Developing rapid, cost-effective assay platforms will also facilitate adoption in resource-limited healthcare environments. Because neuro-oncology requires multi-modal precision strategies, combining epigenetic biomarkers with advanced neuroimaging and digital pathology represents an exciting clinical frontier. Ultimately, unraveling sex differences in glioblastoma biology will drive the development of tailored therapies, optimizing survival outcomes for all patients facing this devastating disease.

Why do glioblastoma outcomes differ between males and females?

Glioblastoma incidence and mortality are higher in males due to fundamental differences in gene expression, immune microenvironments, and epigenetic regulation. Distinct DNA methylation profiles alter key tumor suppressor and oncogenic pathways differently between sexes, directly influencing tumor aggressiveness, therapeutic response, and overall survival trajectories in affected patients.

What is the clinical role of DNA methylation panels in glioblastoma?

DNA methylation panels identify distinct epigenetic subgroups that predict patient survival at initial surgical resection. By capturing sex-specific alterations in key regulatory genes, these biomarker panels help clinicians refine prognostic stratification, tailor postoperative therapeutic intensity, and identify candidates who may benefit from specialized clinical trials or closer monitoring.

Can sex-specific epigenetic biomarkers change current glioblastoma treatment guidelines?

While current clinical guidelines apply uniform treatment protocols regardless of patient sex, emerging evidence on sex-divergent epigenetic subgroups provides a strong rationale for personalized approaches. Prospective clinical validation may eventually lead to sex-informed therapeutic strategies, including optimized chemotherapeutic dosages, targeted epigenetic drugs, and refined patient stratification in future clinical trials.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding clinical decisions, diagnosis, or treatments. Refer to the latest local and national guidelines for clinical practice.

References

1. Kiesel B et al. Sex-specific differences in DNA methylation defining prognostically relevant subgroups in glioblastoma. J Neurosurg. 2025 Jul 01. doi: 10.3171/2024.9.JNS24665. PMID: 39951709.


2. Ostrom QT et al. Sex, Age, and Race/Ethnicity Disparities in Incidence and Survival of Gliomas in the United States, 2000-2014. Mol Cancer Res. 2018;16(8):1258-1268.


3. Capper D et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469-474.